Trial
NCT02783573
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
AstraZeneca
Collaborators
Eli Lilly and Company
Condition
Alzheimer's Disease
Intervention
Lanabecestat
Why stopped
An independent assessment concluded the trial was not likely to meet the primary endpoint upon completion and therefore, trial stopped for futility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-12-03